Patents Assigned to Merck Sharp & Dohme Corporation
  • Mono- and di-PEG IL-10 production; and uses
    Patent number: 9259478
    Abstract: Provided are methods of producing mono- and di-pegylated IL-10.
    Type: Grant
    Filed: February 18, 2014
    Date of Patent: February 16, 2016
    Assignee: Merck Sharp & Dohme Corporation
    Inventors: Steven J. Blaisdell, Collette M. Cutler, Brittany C. Paporello, Alexandre Ambrogelly
  • Pegylated interleukin-10
    Patent number: 9238079
    Abstract: Interleukin-10 (IL-10) conjugated via a linker to one or more polyethylene glycol (PEG) molecules at a single amino acid residue of the IL-10, and a method for preparing the same, are provided. The method produces a stable mono-pegylated IL-10, which retains IL-10 activity, where pegylation is selective for the N-terminus on one subunit of IL-10 with little or no formation of monomeric IL-10. The method also provides a substantially homogenous population of mono-PEG-IL-10.
    Type: Grant
    Filed: February 21, 2014
    Date of Patent: January 19, 2016
    Assignee: Merck Sharp & Dohme Corporation
    Inventors: Seoju Lee, David C. Wylie, Susan Cannon-Carlson
  • DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
    Publication number: 20150011590
    Abstract: The present invention is directed to novel substituted dihydropyrrolopyrazoles of structural Formula I which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.
    Type: Application
    Filed: February 12, 2013
    Publication date: January 8, 2015
    Applicant: Merck Sharp & Dohme Corporation
    Inventors: Ann E. Weber, Tesfaye Biftu
  • Inhibitors of diacylglycerol acyltransferase
    Patent number: 8716312
    Abstract: The present invention relates to novel heterocyclic compounds as diacylglycerol acyltransferase (“DGAT”) inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose.
    Type: Grant
    Filed: November 17, 2009
    Date of Patent: May 6, 2014
    Assignee: Merck Sharp & Dohme Corporation
    Inventors: Pauline C. Ting, Robert Aslanian, Mary Ann Caplen, Jianhua Cao, Tin-Yau Chan, David Kim, Hyunjin Kim, Jae-Hun Kim, Rongze Kuang, Joe F. Lee, John Schwerdt, Heping Wu, Nicolas Zorn
  • Pegylated interleukin-10
    Patent number: 8697045
    Abstract: Interleukin-10 (IL-10) conjugated via a linker to one or more polyethylene glycol (PEG) molecules at a single amino acid residue of the IL-10, and a method for preparing the same, are provided. The method produces a stable mono-pegylated IL-10, which retains IL-10 activity, where pegylation is selective for the N-terminus on one subunit of IL-10 with little or no formation of monomeric IL-10. The method also provides a substantially homogenous population of mono-PEG-IL-10.
    Type: Grant
    Filed: August 26, 2011
    Date of Patent: April 15, 2014
    Assignee: Merck Sharp & Dohme Corporation
    Inventors: Seoju Lee, David C. Wylie, Susan Cannon-Carlson
  • Mono- and di-PEG IL-10 production; and uses
    Patent number: 8691205
    Abstract: Provided are methods of producing a mixture of mono- and di-pegylated IL-10.
    Type: Grant
    Filed: December 15, 2009
    Date of Patent: April 8, 2014
    Assignee: Merck Sharp & Dohme Corporation
    Inventors: Steven J. Blaisdell, Collette M. Cutler, Brittany C. Paporello, Alexandre Ambrogelly
  • COMBINATION THERAPY USING A BETA 3 ADRENERGIC RECEPTOR AGONISTS AND AN ANTIMUSCARINIC AGENT
    Publication number: 20120202819
    Abstract: Described herein is an improved method of treating overactive bladder, wherein the method comprises administering to a patient in need thereof a beta 3 adrenergic receptor agonist, an antimuscarinic agent, and an optional selective M2 antagonist. Such combination therapy provides improved efficacy and/or reduced side effects.
    Type: Application
    Filed: September 27, 2010
    Publication date: August 9, 2012
    Applicant: Merck Sharp & Dohme Corporation
    Inventors: Scott D. Edmondson, Mary Struthers SinhaRroy, Hiroshi Nagabukuro, William S. Denney, Tara F. Frenki